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One hundred recent clinical Pseudomonas aeruginosa isolates were used to assess the quantitative (MIC) and
qualitative (susceptibility category) accuracies of the MicroScan WalkAway, VITEK, and VITEK 2 automated
susceptibility test systems when five-broad spectrum -lactams, aztreonam, cefepime, ceftazidime, imipenem,
and piperacillin-tazobactam, were tested. Isolates were selected so that the MICs for the isolates overrepre-
sented the MICs near the breakpoints to assess precisely the agreement between the results obtained with the
automated systems and the results obtained by the reference tests. The categorical and MIC results from the
automated systems were compared to the consensus result of three reference methods: broth microdilution,
agar dilution, and disk diffusion. The consensus categorical testing (susceptibility and resistance) rates were
47 and 27%, respectively, for aztreonam; 59 and 14%, respectively, for cefepime; 44 and 43%, respectively, for
ceftazidime; 71 and 19%, respectively, for imipenem; and 50 and 50%, respectively, for piperacillin-tazobactam.
All systems tested exhibited a high, unacceptable level of very major (false-susceptible) errors for piperacillin-
tazobactam (19 to 27%). Major (false-resistant) error rates were generally acceptable (0 to 3%), but minor
error rates were elevated (8 to 32%) for cefepime (VITEK 2 and VITEK) and for aztreonam (all three systems),
leading to consistent trends toward false resistance. Manufacturer reevaluation of these automated systems for
the testing of selected -lactams with current clinical isolates of P. aeruginosa that exhibit contemporary
resistance mechanisms would be prudent to minimize the potential for serious reporting errors.
Automated or semiautomated systems have been widely
used for species identification and susceptibility testing due to
the increasing volumes of clinical specimens processed by clin-
ical laboratories, perceived cost-effectiveness, and convenient
interfaces with laboratory and hospital information systems.
These systems are able to decrease the in-laboratory turnaround
time compared to that required for standardized methods and
supply physicians with susceptibility profiles to help them guide
antimicrobial therapy (8, 21). Each system has inherent strengths
as well as recognized limitations. Unfortunately, reporting errors
by any test system can have serious implications for the clinical
outcome for patients (16). Numerous studies have reported on
the accuracies of various automated systems when several organ-
ism-antimicrobial combinations are tested. The most frequently
reported errors have involved Pseudomonas aeruginosa and select
members of the family Enterobacteriaceae, especially when these
organisms are tested against -lactam antimicrobial agents (1, 2,
4, 10–15, 19, 21, 22). Negative results of such studies have encour-
aged the updating of product software and the periodic issuance
of manufacturer notices recommending alternative testing meth-
ods for certain organism-antimicrobial combinations.
Several mechanisms may lead to resistance to broad-spec-
trum -lactams among gram-negative bacteria, including (i)
the hyperproduction of AmpC -lactamase or other broad-
spectrum -lactamases, such as various carbapenemases; (ii)
decreased outer membrane permeability (porin deletion); and
(iii) active efflux. Some of these mechanisms may preferentially
affect particular -lactam compounds, and some automated
systems may have problems in correcting interpretive results
(11, 13, 22). Variations in inoculum concentrations and incu-
bation times may also affect the detection of resistance sec-
ondary to -lactamase production. Thus, rapid automated sus-
ceptibility testing systems may have difficulty in detecting
resistance to some -lactam compounds for technical reasons,
including the methodologies used by the test system and soft-
ware calculations due to the underlying resistance mechanisms
of the organism (1, 2, 7, 11).
Recent reports from an increasing number of hospitals of
antibiogram inconsistencies between broad-spectrum ceph-
alosporins and piperacillin-tazobactam when P. aeruginosa is
tested drew our attention to possible technical problems with
the prevailing automated test systems. In this study, we evalu-
ated the antimicrobial susceptibility testing accuracies of three
commonly used automated systems, the MicroScan WalkAway
system (Dade Behring, Deerfield, IL) and the VITEK and
VITEK 2 systems (bioMerieux, Hazelwood, MO), against a
challenge collection of P. aeruginosa isolates and five anti-
pseudomonal -lactams: aztreonam, cefepime, ceftazidime,
imipenem, and piperacillin-tazobactam.
One hundred recent clinical strains of P. aeruginosa from
hospitals worldwide were evaluated. The isolates were selected
according to cefepime and piperacillin-tazobactam MIC re-
sults to overrepresent strains that fall within 2 log2 dilutions
of current Clinical and Laboratory Standards Institute (CLSI;
formerly the National Committee for Laboratory Standards)
susceptible and resistance breakpoints (Table 1) (5, 17, 18).
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This would allow the detection of systemic errors and facilitate
the characterization of the errors in log2 dilution steps.
The susceptibilities of all isolates were tested by three ref-
erence methods, by two other manual standardized methods,
and with the three cited automated systems. The broth mi-
crodilution (frozen panels), agar dilution, and disk diffusion
methods were used as reference benchmarks to establish con-
sensus categorical and MIC results for each organism-antimi-
crobial combination (5, 17, 18). In addition, commercially pre-
pared dry-form panels (TREK Diagnostics, Cleveland, OH)
and E-test (AB BIODISK, Solna, Sweden) were used to fur-
ther confirm the consensus MIC, when needed. The Mi-
croScan WalkAway tests were performed at a commercial lab-
oratory (Weland Clinic, Cedar Rapids, IA) by using a gram-
negative MIC panel type 30 (B1017-308). The VITEK 2 tests
were performed at a university medical center laboratory (Uni-
versity of Washington, Seattle, WA) with GN09 susceptibility
cards, and the results were analyzed with advanced expert
system software, version WSVT2-R03.01. The VITEK and all
reference and standardized test methods were performed at
JMI Laboratories (North Liberty, IA). VITEK GNS-122 sus-
ceptibility cards were used with the VITEK system, and the
data were interpreted by using software version WSVTK-
R09.01. All tests by the reference and standardized methods
and automated system susceptibility testing were performed in
compliance with current CLSI methods (M7-A6 and M7-A8)
(17, 18) and/or as recommended by the manufacturers’ pack-
age inserts with the products. Quality control was monitored by
using the following organisms: Staphylococcus aureus ATCC
29213, Enterococcus faecalis ATCC 29212, P. aeruginosa ATCC
27853 and Escherichia coli ATCC 25922 and ATCC 35218 (5).
Consensus categorical results were initially obtained by com-
paring the results of the frozen broth microdilution and agar
dilution methods (5, 17), which were the methods used to
establish and validate each automated method. The agreement
between both methods was considered the “consensus result.”
If the results of these test methods did not agree, discords were
resolved by the CLSI disk diffusion method (18). Categorical
consensus results were obtainable for 100.0% of the strains by
these three methods. The categorical results of each auto-
mated system were then compared to the consensus results.
Categorical disagreements were classified as very major errors
(false susceptibility), major errors (false resistance), and minor
errors (involving the intermediate category interpretation).
The MIC consensus results were also calculated by the fro-
zen broth microdilution and agar dilution methods. If the MIC
results of these methods were different, the disk diffusion test
result was consulted if a categorical shift was involved. As an
example, if the ceftazidime results were 16 and 32 g/ml and
the disk diffusion provided a resistant result, the consensus
MIC was established at 32 g/ml. If a consensus MIC could not
be achieved by these three methods, the dry-form broth mi-
crodilution and E-test results were sequentially compared to
determine a log2 quantitative value.
Table 1 shows the distribution of the consensus MIC results
for the P. aeruginosa strains. The proportions of MIC results
within 1 log2 dilution of the breakpoints were 90% for
aztreonam, 75% for cefepime, 62% for ceftazidime, 64% for
imipenem, and 59% for piperacillin-tazobactam (Table 1).
Based upon the consensus results for P. aeruginosa, the rates
of susceptibility and resistance were as follows: 47 and 27%,
respectively, for aztreonam; 59 and 14%, respectively, for
cefepime; 44 and 43%, respectively, for ceftazidime; 71 and
19%, respectively, for imipenem; and 50 and 50%, respectively,
for piperacillin-tazobactam (Table 2).
The highest numbers of intermethod discords were detected
when piperacillin-tazobactam was tested, with all automated
systems showing a clear tendency toward false-susceptible re-
sults (very major errors). Piperacillin-tazobactam consensus
susceptibility rates increased from 50% to 68% (MicroScan
WalkAway system), 71% (VITEK system), and 78% (VITEK 2
TABLE 1. Consensus MICsa for the challenge collection of P.
aeruginosa strains (n  100) used in evaluation of commercial MIC
products
Antimicrobial
No. of strains at the following MIC (g/ml):
1 2 4 8 16 32 64 128 256 512
Aztreonam NTb 4 21 22c 26 18d 3 3 3 NT
Cefepime 6 15 13 25c 27 9d 1 2 2 NT
Ceftazidime 5 19 13 7c 13 15d 14 6 8 NT
Imipenem 31 32 8c 10 13d 1 0 5 NT NT
Piperacillin-
tazobactam
NT NT 11 14 6 9 10c 23d 17 10
a Consensus MICs were defined as identical reference agar dilution and broth
microdilution MIC results; discords were resolved by using dry-form broth mi-
crodilution panels and E-test.
b NT, concentration not tested.
c Susceptible breakpoint.
d Resistance breakpoint.
TABLE 2. Evaluation of accuracies of three automated systems





Consensusa MicroScanWalkAway VITEK 2 VITEK
Aztreonam
Susceptible 47 41 33 49
Intermediate 26 32 41 14
Resistant 27 27 26 37
Cefepime
Susceptible 59 39 57b 44
Intermediate 27 29 22 35
Resistant 14 32 21 21
Ceftazidime
Susceptible 44 43 44 42
Intermediate 13 16 12 20
Resistant 43 41 44 38
Imipenem
Susceptible 71 68 72b 69
Intermediate 10 9 14 1
Resistant 19 23 14 30
Piperacillin-tazobactam
Susceptible 50 68 78b 71
Resistant 50 32 22 29
a Consensus result among the broth microdilution (frozen dry-form panels),
agar dilution, and disk diffusion methods.
b The system did not provide results for one strain.
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system). Thus, the rates of very major errors when this agent
was tested were 27% for the VITEK 2 system, 21% for the
VITEK system, and 19% for the MicroScan WalkAway system,
while major errors were detected only with the MicroScan
WalkAway system (1%) (Table 3).
When cefepime was tested, the major error rates did not
exceed 3% (the MicroScan WalkAway system results were at
the upper end of acceptable performance) (Table 3). In con-
trast, however, the rates of minor errors were usually high for
all combinations (8 to 32%), reflecting the high number of
isolates whose breakpoints were within 1 log2 dilution of
the categorical breakpoints (Tables 1 and 3). When aztreo-
nam was tested, a clear tendency toward less susceptible
results was detected with the VITEK 2 system (a shift from
susceptible to intermediate) and the VITEK system (a shift
from intermediate to resistant) (Tables 2 and 3). A similar
trend was discovered with cefepime, especially when it was
tested on the MicroScan WalkAway system. The cefepime
susceptibility rates dropped from 59% (consensus) to only 39%
(MicroScan WalkAway system) and 44% (VITEK system),
while the cefepime resistance rates increased from 14% (con-
sensus) to 32% (MicroScan WalkAway system) and 21%
(VITEK 2 and VITEK systems). In addition, a slight tendency
toward more resistant results (a shift from intermediate to
resistant) was observed when imipenem was tested with the
VITEK system.
P. aeruginosa has become the most common gram-negative
bacterial species associated with serious nosocomial infections
in many hospitals, particularly within intensive care units (9,
23). The accurate determination of P. aeruginosa antimicrobial
susceptibility is critical for both the immediate management of
infected patients and the timely introduction of appropriate
infection control measures. The attributable mortality rate as-
sociated with P. aeruginosa infection has been reported to be
greater than 20%, and the rapid application of appropriate
antimicrobial treatment has been associated with improved clin-
ical outcomes. Conversely, other studies have demonstrated that
inappropriate initial antimicrobial therapy is associated with
higher rates of patient morbidity and mortality as a result of
infections caused by P. aeruginosa (16).
The automated systems evaluated in this study are market
leaders in the United States and many other countries (6, 19).
A recent survey of the College of American Pathologists with
a P. aeruginosa isolate indicated that 5.9% of respondents
using an automated test system reported a false-susceptible
result for a highly resistant challenge organism (6). That survey
also indicated that 29.5% of responses from laboratories that
used the VITEK 2 system (46 of 156 results) were falsely
susceptible to piperacillin-tazobactam (MICs  64 g/ml).
This was an unacceptable level of performance for those
laboratories reporting the organism as falsely susceptible to
piperacillin-tazobactam, given that the P. aeruginosa strain had
a piperacillin-tazobactam MIC of 1,024 g/ml by reference
methods (17). Those results were confirmed by our findings
with the VITEK 2 system and the -lactamase inhibitor com-
bination.
The results of this study dramatically demonstrated that
the automated systems studied (the MicroScan WalkAway,
VITEK 2, and VITEK systems) generally failed to accurately
detect piperacillin-tazobactam resistance among clinically sig-
nificant isolates of P. aeruginosa. All three systems showed high
and unacceptable rates of very major errors (19 to 27%). It is
important to emphasize that these results should be interpreted
in light of the criteria used to select the strains (MICs close
to the breakpoints or within the resistance range); this pop-
ulation was chosen to increase the sensitivity of detecting and
quantifying significant categorical disagreements. It is also impor-
tant that data from the SENTRY Antimicrobial Surveillance Pro-
gram indicate that the majority of piperacillin-tazobactam-resis-
tant strains (MICs  128 g/ml) show piperacillin-tazobactam
MIC results at or only 1 log2 dilution higher (128 to 256 g/ml)
than the resistance breakpoint, therefore emphasizing the impor-
tance of those errors and the validity of the strains selected for use
in this experiment (Table 1). Among 397 P. aeruginosa strains
evaluated by the USA SENTRY Program (2003), 34 (8.6%) were
resistant to piperacillin-tazobactam; and 28 (82%) of those strains
showed piperacillin-tazobactam MICs of 128 or 256 g/ml (H. S.
Sader, D. J. Biedenbach, T. R. Fritsche, and R. N. Jones. Abstr.
105th Gen. Meet. Am. Soc. Microbiol., abstr. C-007, 2005).
Earlier studies of P. aeruginosa isolates from cystic fibrosis
patients (mucoid and nonmucoid isolates) have established the
accuracies of the CLSI reference methods (20) and the agar
diffusion methods (disk diffusion and E-test) (3) but recog-
nized that the VITEK and the MicroScan WalkAway systems
were not recommended for use for the testing of this species
(4). The trends toward false-intermediate and -resistant results
by automated methods with cefepime and aztreonam have also
become a chronic problem (1, 2, 11, 19), leading to inaccura-
cies in local antibiograms and the selection of alternative
agents for individual patient therapy. Thus, the high rates of
TABLE 3. Evaluation of accuracies of automated systems for






WalkAway VITEK 2 VITEK
Aztreonam
Very major 0 0 2
Major 0 1 2
Minor 28 31 28
Cefepime
Very major 0 0 0
Major 3 1 0
Minor 32 18 26
Ceftazidime
Very major 0 1 2
Major 0 1 0
Minor 13 9 11
Imipenem
Very major 0 1 0
Major 2 2 2
Minor 10 8 11
Piperacillin-tazobactam
Very major 19 27 21
Major 1 0 0
a Error rates were calculated based on the consensus result among the broth
microdilution (frozen dry-form panels), agar dilution, and disk diffusion methods.
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false-susceptible and false-resistant results provided by the au-
tomated systems may have a significant impact on formulary
positioning of antipseudomonal agents and, ultimately, guide-
lines for the empirical treatment of P. aeruginosa infections in
medical centers worldwide. Reevaluation of the -lactam in-
terpretative algorithms of these systems for tests with P. aerugi-
nosa would be prudent to minimize or eliminate the biases
detected and correct the various types of errors detected com-
pared to the results of recognized reference methodologies (5,
17, 18).
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